Objective In the 6 years since the National Library of Medicine began monthly releases of RxNorm, RxNorm has become a central resource for communicati

DrugCentral (http://drugcentral.org) is an open-access online drug compendium. DrugCentral integrates structure, bioactivity, regulatory, pharmacologic actions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies. Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date. DrugCentral integrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug label annotations, complementing similar resources available online. Its complementarity with other online resources is facilitated by cross referencing to external resources. At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and indications. The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information. Chemical structure overlap between DrugCentral and five online drug resources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed. DrugCentral can be accessed via the web application or downloaded in relational database format.

Commercial drug information systems follow a variety of naming conventions. A smooth electronic exchange of the information in these systems - not only between organizations but even within a single organization - is crucial in assuring patient safety. This exchange requires a standardized nomenclature. To meet this need, the National Library of Medicine (NLM) created RxNorm, a standardized nomenclature for clinical drugs that is one of a suite of standards designated for use in US federal government systems for the electronic exchange of clinical health information.

Lyme disease is characterized by skin, joint, heart, and central or peripheral neurologic disease. We studied a patient with typical Lyme disease, including a demyelinating neuropathy, who had many characteristics of the Guillain-Barré syndrome, although it was accompanied by CSF pleocytosis. Immunologic abnormalities occurring in Lyme disease suggest immune pathogenesis of the peripheral demyelination.